|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-4-30
|
|
pubmed:abstractText |
Oral fludarabine is the first oral formulation of a purine analogue available for clinical use which has produced encouraging results in patients with B-cell chronic lymphocytic leukemia (CLL). It has a similar tolerability profile to that of the intravenous formulation. Acute tumor lysis syndrome (TLS) induced by fludarabine appears to be a fairly unusual complication during the treatment of CLL.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1423-0240
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
2008 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
197-9
|
|
pubmed:meshHeading |
pubmed-meshheading:18418022-Administration, Oral,
pubmed-meshheading:18418022-Aged,
pubmed-meshheading:18418022-Antineoplastic Agents,
pubmed-meshheading:18418022-Humans,
pubmed-meshheading:18418022-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:18418022-Male,
pubmed-meshheading:18418022-Treatment Outcome,
pubmed-meshheading:18418022-Tumor Lysis Syndrome,
pubmed-meshheading:18418022-Urate Oxidase,
pubmed-meshheading:18418022-Vidarabine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
|
|
pubmed:affiliation |
Department of Hematology, Hospital General de Lanzarote, Arrecife de Lanzarote, Spain. jmcvillas@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
